Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake.

ABSTRACT:

Background

The therapeutic use of [¹³¹I]meta-iodobenzylguanidine ([¹³¹I]MIBG) is often accompanied by hematological toxicity, mainly consisting of persistent and severe thrombocytopenia. While MIBG accumulates in neuroblastoma cells via selective uptake by the norepinephrine transporter (NET), the serotonin transporter (SERT) is responsible for cellular uptake of MIBG in platelets. In this study, we have investigated whether pharmacological intervention with selective serotonin reuptake inhibitors (SSRIs) may prevent radiotoxic MIBG uptake in platelets without affecting neuroblastoma tumor uptake.

Methods

To determine the transport kinetics of SERT for [¹²⁵I]MIBG, HEK293 cells were transfected with SERT and uptake assays were conducted. Next,

SUBMITTER: Blom T 

PROVIDER: S-EPMC7343696 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature